<DOC>
	<DOCNO>NCT00624364</DOCNO>
	<brief_summary>This trial conduct Africa . The aim trial evaluate efficacy safety biphasic insulin aspart plus OAD compare biphasic insulin aspart alone blood glucose control type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Safety Biphasic Insulin Aspart 30 With Metformin Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 2 diabetes Currently treat maximum dos kind OAD alone kind oral combination therapy least 2 month Body mass index ( BMI ) 40.0 kg/m2 HbA1c 7.513.0 % History drug alcohol dependence Mental incapacity , unwillingness language barrier preclude adequate Subjects previously screen participation already participate trial Receipt investigational drug within last month prior trial Known suspect allergy trial product relate product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>